Showing results (1801-1810 of 8,157) with videos related to
Sort By:
Pageof 816
Haematologica|March 20, 2025
NPM1 mutation subtype switch in acute myeloid leukemiaBenjamin Podvin, Romane Joudinaud, Christophe Roumier, et al.Haematologica|March 13, 2025
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trialRichard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.Haematologica|March 13, 2025
Safe platelet count for lumbar puncture: are we being overcautious?Talha BadarHaematologica|March 13, 2025
Regulation of immune responses to therapeutic factor VIII by transplacental delivery of Fc-fused immunodominant factor VIII domains or peptidesAlejandra Reyes-Ruiz, Sandrine Delignat, Aurélien Azam, et al.Haematologica|March 6, 2025
Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolismCatherine Duane, Siobhan Glavey, John Quinn, et al.Haematologica|March 6, 2025
Inter-platelet communication driving thrombus formation is regulated by extracellular calpain-1 cleavage of connexin 62Kirk A Taylor, Amro Elgheznawy, Recep Adiyaman, et al.Haematologica|March 20, 2025
Clonal hematopoiesis is common in bone marrow of patients with classical Hodgkin lymphomaRebeca Iglesias, Eva Díaz, Sara Fernández, et al.Haematologica|March 20, 2025
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trialSalomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.Haematologica|October 24, 2024
Treatment of lower-risk myelodysplastic syndromesAlmuth Maria Anni Merz, Uwe PlatzbeckerHaematologica|October 24, 2024
Pathogenesis and inflammaging in myelodysplastic syndromeMatthew T Villaume, Michael R SavonaPageof 816